INmune Bio Net Worth
INmune Bio Net Worth Breakdown | INMB |
INmune Bio Net Worth Analysis
INmune Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including INmune Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of INmune Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform INmune Bio's net worth analysis. One common approach is to calculate INmune Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares INmune Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing INmune Bio's net worth. This approach calculates the present value of INmune Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of INmune Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate INmune Bio's net worth. This involves comparing INmune Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into INmune Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if INmune Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding INmune Bio's net worth research are outlined below:
| INmune Bio generated a negative expected return over the last 90 days | |
| INmune Bio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 14 K. Net Loss for the year was (42.08 M) with profit before overhead, payroll, taxes, and interest of 50 K. | |
| INmune Bio currently holds about 61.21 M in cash with (33.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| INmune Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: When Moves Investors should Listen - news.stocktradersdaily.com |
INmune Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in INmune Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to INmune Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
INmune Bio Target Price Consensus
INmune target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. INmune Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most INmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand INmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of INmune Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationINmune Bio Target Price Projection
INmune Bio's current and average target prices are 2.86 and 23.40, respectively. The current price of INmune Bio is the price at which INmune Bio is currently trading. On the other hand, INmune Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On INmune Bio Target Price
Know INmune Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as INmune Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading INmune Bio backward and forwards among themselves. INmune Bio's institutional investor refers to the entity that pools money to purchase INmune Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2025-03-31 | 101.5 K | Appleseed Capital | 2025-03-31 | 94.3 K | Westside Investment Management, Inc. | 2025-03-31 | 89.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 84.5 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 58.1 K | Bank Of New York Mellon Corp | 2025-03-31 | 54.9 K | Waratah Capital Advisors Ltd | 2025-03-31 | 53.8 K | Fermata Advisors, Llc | 2025-03-31 | 50 K | Simplex Trading, Llc | 2025-03-31 | 42.8 K | Blackrock Inc | 2025-03-31 | 948.4 K | Praetorian Pr Llc | 2025-03-31 | 865 K |
Follow INmune Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.38 M.Market Cap |
|
Project INmune Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.83) | (1.92) | |
| Return On Capital Employed | (1.32) | (1.25) | |
| Return On Assets | (1.06) | (1.12) | |
| Return On Equity | (1.31) | (1.25) |
When accessing INmune Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures INmune Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of INmune Bio's profitability and make more informed investment decisions.
Please note, the presentation of INmune Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, INmune Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of INmune Bio's management manipulating its earnings.
Evaluate INmune Bio's management efficiency
INmune Bio has return on total asset (ROA) of (0.6133) % which means that it has lost $0.6133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3901) %, meaning that it created substantial loss on money invested by shareholders. INmune Bio's management efficiency ratios could be used to measure how well INmune Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of July 24, 2025, Return On Tangible Assets is expected to decline to -1.92. The current year's Return On Capital Employed is expected to grow to -1.25. At present, INmune Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 52.6 M, whereas Non Current Assets Total are forecasted to decline to about 16.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.61 | 1.66 | |
| Tangible Book Value Per Share | 0.78 | 0.88 | |
| Enterprise Value Over EBITDA | (1.73) | (1.81) | |
| Price Book Value Ratio | 2.90 | 3.05 | |
| Enterprise Value Multiple | (1.73) | (1.81) | |
| Price Fair Value | 2.90 | 3.05 | |
| Enterprise Value | 72.6 M | 82.1 M |
INmune Bio has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 916.829 | Revenue | Quarterly Revenue Growth 2.571 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific INmune Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on INmune Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases INmune Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
INmune Bio time-series forecasting models is one of many INmune Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary INmune Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
INmune Bio Earnings Estimation Breakdown
The calculation of INmune Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of INmune Bio is estimated to be -0.4267 with the future projection ranging from a low of -0.46 to a high of -0.37. Please be aware that this consensus of annual earnings estimates for INmune Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.46 Lowest | Expected EPS | -0.37 Highest |
INmune Bio Earnings Projection Consensus
Suppose the current estimates of INmune Bio's value are higher than the current market price of the INmune Bio stock. In this case, investors may conclude that INmune Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and INmune Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 6 | 74.21% | -0.43 | -0.4267 | -1.93 |
INmune Bio Earnings per Share Projection vs Actual
Actual Earning per Share of INmune Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering INmune Bio predict the company's earnings will be in the future. The higher the earnings per share of INmune Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.INmune Bio Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as INmune Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of INmune Bio should always be considered in relation to other companies to make a more educated investment decision.INmune Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact INmune Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-05-08 | 2025-03-31 | -0.49 | -0.43 | 0.06 | 12 | ||
2025-03-26 | 2024-12-31 | -0.54 | -0.4 | 0.14 | 25 | ||
2024-10-31 | 2024-09-30 | -0.5 | -0.6 | -0.1 | 20 | ||
2024-08-01 | 2024-06-30 | -0.63 | -0.5 | 0.13 | 20 | ||
2024-05-09 | 2024-03-31 | -0.53 | -0.61 | -0.08 | 15 | ||
2024-03-28 | 2023-12-31 | -0.44 | -0.47 | -0.03 | 6 | ||
2023-11-01 | 2023-09-30 | -0.39 | -0.48 | -0.09 | 23 | ||
2023-08-07 | 2023-06-30 | -0.4 | -0.36 | 0.04 | 10 | ||
2023-05-03 | 2023-03-31 | -0.02 | -0.36 | -0.34 | 1700 | ||
2023-03-02 | 2022-12-31 | -0.48 | -0.32 | 0.16 | 33 | ||
2022-11-02 | 2022-09-30 | -0.52 | -0.43 | 0.09 | 17 | ||
2022-08-03 | 2022-06-30 | -0.5 | -0.38 | 0.12 | 24 | ||
2022-05-05 | 2022-03-31 | -0.64 | -0.39 | 0.25 | 39 | ||
2022-03-03 | 2021-12-31 | -0.58 | -0.55 | 0.03 | 5 | ||
2021-11-03 | 2021-09-30 | -0.35 | -0.55 | -0.2 | 57 | ||
2021-08-04 | 2021-06-30 | -0.34 | -0.44 | -0.1 | 29 | ||
2021-05-05 | 2021-03-31 | -0.27 | -0.32 | -0.05 | 18 | ||
2021-03-04 | 2020-12-31 | -0.31 | -0.26 | 0.05 | 16 | ||
2020-11-05 | 2020-09-30 | -0.17 | -0.36 | -0.19 | 111 | ||
2020-08-05 | 2020-06-30 | -0.2 | -0.2 | 0.0 | 0 | ||
2020-05-14 | 2020-03-31 | -0.21 | -0.19 | 0.02 | 9 | ||
2020-03-11 | 2019-12-31 | -0.25 | -0.22 | 0.03 | 12 | ||
2019-11-08 | 2019-09-30 | -0.19 | -0.28 | -0.09 | 47 | ||
2019-08-09 | 2019-06-30 | -0.19 | -0.19 | 0.0 | 0 | ||
2019-05-15 | 2019-03-31 | -0.19 | -0.2 | -0.01 | 5 | ||
2019-03-29 | 2018-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2018-12-21 | 2018-09-30 | 0 | -0.04 | -0.04 | 0 | ||
2018-08-30 | 2018-06-30 | 0 | -0.55 | -0.55 | 0 | ||
2018-06-13 | 2018-03-31 | 0 | -0.25 | -0.25 | 0 | ||
2017-12-01 | 2017-09-30 | 0 | -0.03 | -0.03 | 0 |
INmune Bio Corporate Management
| Christopher Barnum | Head Neuroscience | Profile | |
| BSc FRCPath | Chief Officer | Profile | |
| Mark Lowdell | Chief Officer | Profile | |
| Raymond MD | President, CoFounder | Profile | |
| Joshua Esq | General Counsel | Profile | |
| David MBA | Treasurer CFO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.93) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.